TTAM will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

This was the stock's second consecutive day of gains.

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Market Domination Overtime hosts Julie Hyman and Josh Lipton preview the top market stories and headlines Wall Street will be paying attention to tomorrow, Friday, June 13, including June's ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...